Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
Yong Feng WangJie Ting TangTao HanHui Guo DingWei Jiang YeMao Rong WangJun ChengYong Ping YangCheng Wei ChenQing XieQing MaoJun Qi NiuZheng Hua WangZhong WeiYing Xuan ChenMin De ZengYi Min MaoPublished in: Journal of digestive diseases (2018)
Tolvaptan at 15 mg/day significantly reduced the body weight and abdominal circumference in patients with liver cirrhosis-associated ascites, which needs to be confirmed in a phase 3 trial.